Phenylpropanolamine has 6 known drug interactions based on U.S. FDA drug labeling data. 3 are classified as major interactions requiring close medical supervision. Notable interactions include combinations with Bromocriptine Mesylate, Warfarin, Warfarin Sodium. Patients taking Phenylpropanolamine should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.
- Total
- 6
- Major
- 3
- Moderate
- 3
Major (3)
- Phenylpropanolamine + Bromocriptine Mesylate— Sympathomimetic drugs may cause hypertension and tachycardia when co-administered with bromocriptine. Use beyond 10 days…
- Phenylpropanolamine + Warfarin— CYP1A2 inhibitor that increases warfarin effect and INR; requires close INR monitoring
- Phenylpropanolamine + Warfarin Sodium— CYP1A2 inhibitor that increases warfarin effect and INR; requires close INR monitoring.
Moderate (3)
- Phenylpropanolamine + Iobenguane I-123— Sympathomimetic amine that may decrease norepinephrine uptake and cause false negative imaging results with iobenguane.
- Phenylpropanolamine + Ioflupane I-123— Binds to dopamine transporter with high affinity and may interfere with Ioflupane I-123 imaging results.
- Phenylpropanolamine + Promethazine Hydrochloride And Phenylephrine Hydrochloride— Phenylephrine with phenylpropanolamine causes synergistic adrenergic response.